Caris Life Sciences (CAI) withholds 13,987 shares for RSU taxes

Rhea-AI Filing Summary

Caris Life Sciences director Brian J. Brille reported routine equity compensation-related activity involving company common stock. On May 15, 2026, 13,987 shares of common stock were withheld at $15.25 per share to cover taxes on the vesting and settlement of RSUs, which is a tax-withholding disposition rather than an open-market sale.

After this tax withholding, Brille directly held 230,303 shares of common stock. In addition, a family trust held 500,000 shares of common stock, reflecting indirect ownership after previously separate family trusts were consolidated into a single trust. Brille disclaims beneficial ownership of these trust-held shares except to the extent of his pecuniary interest.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Brille Brian J

Role See Remarks

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	13,987	$15.25	$213K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 230,303 shares (Direct, null); Common Stock — 500,000 shares (Indirect, By Trust)

Footnotes (1)

1. Shares withheld for the payment of taxes on the vesting and settlement of RSUs. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein. By a family trust, with shares previously held in multiple family trusts consolidated into a single trust.

Key Figures

Tax-withheld shares: 13,987 shares Tax-withholding price: $15.25 per share Direct holdings after transaction: 230,303 shares +1 more

4 metrics

Tax-withheld shares 13,987 shares Withheld for RSU tax payment at $15.25 per share on May 15, 2026

Tax-withholding price $15.25 per share Value used for 13,987 RSU-related tax-withheld shares

Direct holdings after transaction 230,303 shares Common stock directly owned by Brian J. Brille after tax withholding

Indirect holdings by trust 500,000 shares Common stock held by a consolidated family trust as indirect ownership

Key Terms

RSUs, tax-withholding disposition, beneficial ownership, family trust

4 terms

RSUs financial

"Shares withheld for the payment of taxes on the vesting and settlement of RSUs."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

family trust financial

"By a family trust, with shares previously held in multiple family trusts consolidated into a single trust."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brille Brian J

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TEXAS 75039

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		F		13,987(1)	D	$15.25	230,303	D
Common Stock								500,000	I	By Trust(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for the payment of taxes on the vesting and settlement of RSUs.

2. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

3. By a family trust, with shares previously held in multiple family trusts consolidated into a single trust.

Remarks:

Vice Chairman and Executive Vice President

	/s/ J. Russel Denton, Attorney-in-Fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Caris Life Sciences (CAI) director Brian J. Brille report on this Form 4?

Brian J. Brille reported routine equity compensation activity. The company withheld 13,987 common shares at $15.25 each to pay taxes due on vested RSUs, and his resulting direct and indirect ownership positions were updated in the filing.

Were the 13,987 Caris Life Sciences (CAI) shares an open-market sale?

No. The 13,987 shares were withheld to cover tax obligations on RSU vesting. This is recorded as a tax-withholding disposition and not as an open-market sale or discretionary trade in Caris Life Sciences shares.

How many Caris Life Sciences (CAI) shares does Brian J. Brille hold after the transaction?

Following the tax withholding, Brille directly holds 230,303 Caris Life Sciences common shares. A separate family trust holds an additional 500,000 shares, reported as indirect ownership in the Form 4 filing.

What does the family trust holding mean for Caris Life Sciences (CAI) insider ownership?

A family trust holds 500,000 Caris Life Sciences shares attributed as indirect ownership. The filing notes these shares were consolidated from multiple family trusts, and Brille disclaims beneficial ownership except for his pecuniary interest in the trust.

What is the significance of the RSU-related tax withholding for Caris Life Sciences (CAI) investors?

The RSU-related tax withholding is a routine administrative event. Shares were withheld to satisfy tax obligations from RSU vesting, rather than sold in the market, so it typically carries limited informational value for assessing Caris Life Sciences’ business performance.